# EaRly impAct theraPy With Ceftazidime-avibactam Via rapID Diagnostics

> **NCT05979545** · PHASE4 · RECRUITING · sponsor: **National University of Singapore** · enrollment: 1900 (estimated)

## Conditions studied

- Blood Stream Infections
- Ventilator Associated Pneumonia
- Healthcare Associated Infection
- Carbapenem-Resistant Enterobacteriaceae Infection
- Hospital-acquired Pneumonia

## Interventions

- **DIAGNOSTIC_TEST:** Rapid Diagnostics

## Key facts

- **NCT ID:** NCT05979545
- **Lead sponsor:** National University of Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-12
- **Primary completion:** 2026-10-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 1900 (ESTIMATED)
- **Last updated:** 2024-03-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05979545

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05979545, "EaRly impAct theraPy With Ceftazidime-avibactam Via rapID Diagnostics". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT05979545. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*